All
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
Rediscovering My Sense of Faith Following a Colon Cancer Diagnosis
Faith, from my perspective, is believing in the unseen, and was something I rediscovered following my colon cancer diagnosis.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer
Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of bladder tumor was beneficial.
GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset
The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.
Treatment Intensification Adoption Differences Across Prostate Cancer
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo Plus Cometyx Safe, Effective in Advanced Renal Cell Carcinoma
Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.
High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer
Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.
Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma
Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.
Padcev May Be Safe in Older Patients With Bladder Cancer
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Are We at Risk of Losing Our Breast Cancer Community?
I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.
Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
Linvoseltamab BLA Resubmission Accepted by FDA for Review
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.
Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.
Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
An Expert Explains Updated Data For Patients With GU Cancers
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.
Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story
Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.
Talzenna Plus Xtandi May Improve Survival in mCRPC
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.